From: Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
Hazard Ratio
95 % CI
p
Delay before treatment
1,00
0,99–1
0,44
≤2 previous treatment lines
0,69
0,27 – 1,74
0,43
Histology : osteoblastic
0,80
0,37 – 1,73
0,57
Treatment by Sirolimus
2,73
1,05 – 7,1
0,04